Aldafermin is a fibroblast growth factor 19 (FGF19) analogue developed for non-alcoholic steatohepatitis.[1][2][3][4]
| Clinical data | |
|---|---|
| Other names | NGM282; NGM-282 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
References
edit- ^ Babu, A.F.; Iannone, V.; Lok, J.; Gomez-Gallego, C.; D'Auria, G.; Vazquez-Uribe, R.; Pihlajamaki, J.; Sommer, M.; Hanhineva, K.; El-Nezami, H.; Kohlemainen, M. (August 2023). "An integrated understanding of the metabolic benefits of a novel double-targeted genetically engineered probiotic expressing aldafermin intervention with dietary change on NAFLD". Atherosclerosis. 379: S32. doi:10.1016/j.atherosclerosis.2023.06.772. S2CID 261379804.
- ^ Rinella, Mary E.; Lieu, Hsiao D.; Kowdley, Kris V.; Goodman, Zachary D.; Alkhouri, Naim; Lawitz, Eric; Ratziu, Vlad; Abdelmalek, Manal F.; Wong, Vincent Wai-Sun; Younes, Ziad H.; Sheikh, Aasim M.; Brannan, Donald; Freilich, Bradley; Membreno, Fernando; Sinclair, Marie; Melchor-Khan, Liza; Sanyal, Arun J.; Ling, Lei; Harrison, Stephen A. (21 September 2023). "A randomized, double-blind, placebo-controlled trial of Aldafermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis". Hepatology. doi:10.1097/HEP.0000000000000607. PMC 10871650. PMID 37732990.
- ^ Harrison, Stephen A; Abdelmalek, Manal F; Neff, Guy; Gunn, Nadege; Guy, Cynthia D; Alkhouri, Naim; Bashir, Mustafa R; Freilich, Bradley; Kohli, Anita; Khazanchi, Arun; Sheikh, Muhammad Y; Leibowitz, Mark; Rinella, Mary E; Siddiqui, Mohammad S; Kipnes, Mark; Moussa, Sam E; Younes, Ziad H; Bansal, Meena; Baum, Seth J; Borg, Brian; Ruane, Peter J; Thuluvath, Paul J; Gottwald, Mildred; Khan, Mujib; Chen, Charles; Melchor-Khan, Liza; Chang, William; DePaoli, Alex M; Ling, Lei; Lieu, Hsiao D (July 2022). "Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial". The Lancet Gastroenterology & Hepatology. 7 (7): 603–616. doi:10.1016/S2468-1253(22)00017-6. PMID 35325622. S2CID 247612032.
- ^ Harrison, Stephen A.; Neff, Guy; Guy, Cynthia D.; Bashir, Mustafa R.; Paredes, Angelo H.; Frias, Juan P.; Younes, Ziad; Trotter, James F.; Gunn, Nadege T.; Moussa, Sam E.; Kohli, Anita; Nelson, Kristin; Gottwald, Mildred; Chang, William C.G.; Yan, Andrew Z.; DePaoli, Alex M.; Ling, Lei; Lieu, Hsiao D. (January 2021). "Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis". Gastroenterology. 160 (1): 219–231.e1. doi:10.1053/j.gastro.2020.08.004. PMID 32781086.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |